Neurocrine Biosciences (NBIX)

• Market cap: $12.7B
• 1 day: -0.10%
• 5 days: -1.09%
• 1 month: 4.34%
• 3 months: 0.53%
• 6 months: -10.12%
• Year to date: -4.53%
• 1 year: 7.92%
• 5 years: 6.90%
• 10 years: 548.92%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Employees: 1,448

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

25% more funds holding in top 10

Funds holding in top 10: 8 [Q2] → 10 (+2) [Q3]

19% more repeat investments, than reductions

Existing positions increased: 232 | Existing positions reduced: 195

7% more call options, than puts

Call options by funds: $79.4M | Put options by funds: $74M

3.01% less ownership

Funds ownership: 94.69% [Q2] → 91.68% (-3.01%) [Q3]

4% less funds holding

Funds holding: 584 [Q2] → 561 (-23) [Q3]

19% less capital invested

Capital invested by funds: $13.1B [Q2] → $10.7B (-$2.44B) [Q3]

25% less first-time investments, than exits

New positions opened: 69 | Existing positions closed: 92

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $114 9% downside
• Avg. target: $149 18% upside
• High target: $190 51% upside

7 analyst ratings

• positive: 4 57%
• neutral: 3 43%
• negative: 0 0%

HC Wainwright & Co. Andrew Fein 37% 1-year accuracy 62 / 169 met price target	51% upside $190	Buy Reiterated	1 Nov 2024
BMO Capital Evan Seigerman 50% 1-year accuracy 3 / 6 met price target	9% downside $114	Market Perform Maintained	17 Oct 2024
Raymond James Danielle Brill 83% 1-year accuracy 10 / 12 met price target	23% upside $155	Outperform Reinstated	10 Oct 2024
RBC Capital Brian Abrahams 9% 1-year accuracy 3 / 32 met price target	6% upside $133	Sector Perform Reiterated	8 Oct 2024
RBC Capital Brian Abrahams 9% 1-year accuracy 3 / 32 met price target	6% upside $133	Sector Perform Maintained	4 Oct 2024